StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Oncotelic Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Oncotelic Therapeutics's operating income for the twelve months ending Jun 30, 2025 was -$3.48M. For fiscal 2025 it was -$3.19M. The highest annual figure on record is -$712.74K in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$3.19M–
FY2024Dec 31, 2024-$3.58M–
FY2023Dec 31, 2023-$6.65M–
FY2022Dec 31, 2022-$9.72M–
FY2021Dec 31, 2021-$9.13M–
FY2020Dec 31, 2020-$7.58M–
FY2019Dec 31, 2019-$4.31M–
FY2018Dec 31, 2018-$712.74K–
FY2017Dec 31, 2017-$13.84M–
FY2016Dec 31, 2016-$13.76M–
FY2015Dec 31, 2015-$13.68M–
FY2014Dec 31, 2014-$12.65M–
FY2013Dec 31, 2013-$8.28M–
FY2012Dec 31, 2012-$8.07M–
FY2011Dec 31, 2011-$11.89M–
FY2010Dec 31, 2010-$18.51M–
FY2009Dec 31, 2009-$31.16M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$843.57K–
Q1 FY2026Mar 31, 2026-$1.85M–
Q2 FY2025Jun 30, 2025-$65.97K–
Q1 FY2025Mar 31, 2025-$101.10K–
Q4 FY2024Dec 31, 2024-$31.45K–
Q3 FY2024Sep 30, 2024-$3.28M-22760.3%
Q2 FY2024Jun 30, 2024-$96.58K–
Q1 FY2024Mar 31, 2024-$167.22K–
Q4 FY2023Dec 31, 2023-$113.46K–
Q3 FY2023Sep 30, 2023$14.48K–
Q2 FY2023Jun 30, 2023-$6.32M–
Q1 FY2023Mar 31, 2023-$264.12K–
Q4 FY2022Dec 31, 2022-$4.53M–
Q3 FY2022Sep 30, 2022-$595.44K–
Q2 FY2022Jun 30, 2022-$256.32K–
Q1 FY2022Mar 31, 2022-$4.34M–
Q4 FY2021Dec 31, 2021-$1.51M–
Q3 FY2021Sep 30, 2021-$1.81M–
Q2 FY2021Jun 30, 2021-$3.76M-27298.1%
Q1 FY2021Mar 31, 2021-$2.04M–
Q4 FY2020Dec 31, 2020-$3.33M–
Q3 FY2020Sep 30, 2020-$1.62M–
Q2 FY2020Jun 30, 2020$13.84K–
Q1 FY2020Mar 31, 2020-$2.65M–
Q4 FY2019Dec 31, 2019-$1.24M–
Q3 FY2019Sep 30, 2019-$930.71K–
Q2 FY2019Jun 30, 2019-$1.16M–
Q1 FY2019Mar 31, 2019-$976.06K–
Q4 FY2018Dec 31, 2018-$154.60K–
Q3 FY2018Sep 30, 2018-$214.03K–
Q2 FY2018Jun 30, 2018-$153.31K–
Q1 FY2018Mar 31, 2018-$795.00K–
Q4 FY2017Dec 31, 2017-$2.44M–
Q3 FY2017Sep 30, 2017-$3.54M–
Q2 FY2017Jun 30, 2017-$3.90M–
Q1 FY2017Mar 31, 2017-$3.97M–
Q4 FY2016Dec 31, 2016-$3.48M–
Q3 FY2016Sep 30, 2016-$3.26M–
Q2 FY2016Jun 30, 2016-$3.67M–

More Oncotelic Therapeutics figures

See a number that looks wrong?